Infralimbic Neurotrophin-3 Infusion Rescues Fear Extinction Impairment in a Mouse Model of Pathological Fear

Neuropsychopharmacology. 2017 Jan;42(2):462-472. doi: 10.1038/npp.2016.154. Epub 2016 Aug 18.

Abstract

The inability to properly extinguish fear memories constitutes the foundation of several anxiety disorders, including panic disorder. Recent findings show that boosting prefrontal cortex synaptic plasticity potentiates fear extinction, suggesting that therapies that augment synaptic plasticity could prove useful in rescue of fear extinction impairments in this group of disorders. Previously, we reported that mice with selective deregulation of neurotrophic tyrosine kinase receptor, type 3 expression (TgNTRK3) exhibit increased fear memories accompanied by impaired extinction, congruent with an altered activation pattern of the amygdala-hippocampus-medial prefrontal cortex fear circuit. Here we explore the specific role of neurotrophin 3 and its cognate receptor in the medial prefrontal cortex, and its involvement in fear extinction in a pathological context. In this study we combined molecular, behavioral, in vivo pharmacology and ex vivo electrophysiological recordings in TgNTRK3 animals during contextual fear extinction processes. We show that neurotrophin 3 protein levels are increased upon contextual fear extinction in wild-type animals but not in TgNTRK3 mice, which present deficits in infralimbic long-term potentiation. Importantly, infusion of neurotrophin 3 to the medial prefrontal cortex of TgNTRK3 mice rescues contextual fear extinction and ex vivo local application improves medial prefrontal cortex synaptic plasticity. This effect is blocked by inhibition of extracellular signal-regulated kinase phosphorylation through peripheral administration of SL327, suggesting that rescue occurs via this pathway. Our results suggest that stimulating neurotrophin 3-dependent medial prefrontal cortex plasticity could restore contextual fear extinction deficit in pathological fear and could constitute an effective treatment for fear-related disorders.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Disease Models, Animal
  • Extinction, Psychological / drug effects*
  • Extinction, Psychological / physiology
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Fear*
  • Female
  • Long-Term Potentiation
  • Male
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Neuronal Plasticity
  • Neurotrophin 3 / administration & dosage*
  • Neurotrophin 3 / physiology
  • Phobic Disorders / physiopathology*
  • Phobic Disorders / prevention & control
  • Prefrontal Cortex / drug effects*
  • Prefrontal Cortex / metabolism
  • Prefrontal Cortex / physiopathology
  • Pyramidal Cells / drug effects
  • Pyramidal Cells / metabolism
  • Receptor, trkC / agonists*
  • Receptor, trkC / genetics
  • Receptor, trkC / physiology

Substances

  • Neurotrophin 3
  • Receptor, trkC
  • Extracellular Signal-Regulated MAP Kinases